摘要
目的探讨冠心病介入治疗患者联合应用阿司匹林与替格瑞洛对机体凝血功能、血小板聚集的影响效果。方法选择2015年11月至2018年12月临汾市人民医院收治的90例冠心病介入治疗患者为研究对象,经随机数字表法分为研究组和对照组,每组45例。两组均接受经皮冠状动脉介入术(PCI)治疗,研究组PCI术后在常规治疗基础上加用阿司匹林、替格瑞洛,对照组PCI术后在常规治疗基础上加用阿司匹林、氯吡格雷。比较两组患者的凝血功能、血小板聚集率以及药物安全性。结果治疗前,两组活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、纤维蛋白原(Fbg)、凝血酶时间(TT)、血小板聚集率(Pagt)等指标比较差异未见统计学意义(P>0.05)。治疗后,研究组APTT、PT、TT、Pagt等指标改善幅度优于对照组(P<0.05)。对照组Fbg水平较治疗前提高(P<0.05),研究组治疗前后Fbg水平比较差异未见统计学意义(P>0.05)。研究组各项药物相关不良反应发生情况与对照组比较,差异未见统计学意义(P>0.05)。结论冠心病患者PCI术后联合应用阿司匹林、替格瑞洛的临床有效性、安全性均较优,可显著改善其凝血功能及血小板聚集状态。
Objective To investigate the effects of ticagrelor and aspirin on the coagulation function and platelet aggregation in patients with coronary heart disease (CHD). Methods A total of 90 patients with CHD treated by interventional therapy in Linfen People’s Hospital from November 2015 to December 2018 were selected as the study subjects. All patients were divided into study group and control group by random number table method, with 45 cases in each group. Two groups of patients with CHD were treated by percutaneous coronary intervention (PCI). The study group received aspirin and ticagrelor on the basis of conventional treatment after PCI. The control group received aspirin and chlorine on the basis of conventional treatment after PCI. The coagulation function, platelet aggregation rate and drug safety were compared between the two groups. Results Before treatment, there were no significant differences in activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (Fbg), thrombin time (TT), platelet aggregation rate (Pagt) between the two groups (P>0.05). After treatment, APTT, PT, TT, Pagt in the study group were better than those in the control group(P>0.05). After treatment, Fbg levels in the control group were higher than those before treatment (P<0.05), but there was no significant difference in Fbg level in the study group before and after treatment (P>0.05). There was no significant difference in the occurrence of adverse reactions between the study group and the control group (P>0.05). Conclusions The clinical efficacy and safety of aspirin and ticagrelor in patients with CHD after PCI are better, which can significantly improve their coagulation function and platelet aggregation status.
作者
冷文俊
Leng Wenjun(Department of Cardiology,Linfen People’s Hospital,Linfen 041000,China)
出处
《中国实用医刊》
2019年第17期103-105,共3页
Chinese Journal of Practical Medicine
关键词
冠心病
介入治疗
替格瑞洛
凝血功能
血小板聚集
Coronary heart disease
Interventional therapy
Ticagrelor
Coagulation
Platelet aggregation
